So, What's the Fallout from EANM'26?

A congress can add a great deal of information without changing the direction of a market. EANM 2026 did something more useful: it made the next set of questions harder to avoid.

Radiopharma arrived in Vienna with a compelling growth story. New isotope routes, larger industrial platforms and a widening set of biological targets offered several ways forward. The disclosures during the meeting gave that story more substance. They also exposed how much work sits between an attractive option and a treatment that can be made, measured and delivered reliably.

Our reading of the fallout is practical. The next round of diligence should spend less time counting options and more time establishing what makes each one usable. That changes the questions for developers, suppliers, investors and the people they need to hire.

The market that walked into Vienna

The industrial backdrop was already changing. Curium's August agreement to merge with Lantheus put the combination of products and infrastructure at the centre of a major transaction. It was an announced agreement, not evidence that integration had already delivered its promised benefits. But it helped frame the commercial question: who could connect the parts of the radiopharma business?

Then, on 12 October, Bristol Myers Squibb reported positive Phase 3 ACTION-1 topline results for RYZ101 in patients whose GEP-NETs had progressed after Lu-177-based therapy. The company reported an improvement in progression-free survival against investigator-selected standard care. This was important pre-congress context, not an EANM result, and it was not a direct comparison of alpha therapy with Lu-177 treatment. Detailed results still mattered.

Together, those announcements made an optimistic reading understandable: industrial platforms were getting bigger, while alpha development had a significant late-stage signal. It would be too strong to call that a measured industry consensus. It was the growth case visible in the public announcements, and a reasonable starting point for the week's conversations.

There was a counterweight. As we explored in The Lu-177 Capacity Number Nobody Publishes, a large supply number does not tell a sponsor how much qualified, available material it can actually use. The same distinction applies further downstream: owning assets and having a working product-specific route are different achievements.

The clinical story became more specific

One of the more useful disclosures came from ITM and Lumara. Their corrected 20 October release described an association between tumour absorbed dose and response in 106 evaluable COMPETE patients who received four cycles of Lu-177-edotreotide. A separate six-patient BETA PLUS study associated lower peptide mass with higher tumour dose.

Those are different analyses with different limits. The selected COMPETE subgroup does not prove that increasing administered activity improves outcomes. The six-patient observation is exploratory, not a general dosing rule. Neither finding establishes that changing isotope supplier improves a product.

The commercial implication is nevertheless worth considering. A development programme needs to understand its own preparation and behaviour in patients. A familiar isotope label is not a substitute for that knowledge. For a sponsor assessing a manufacturing change, the useful conversation joins the process specification, analytical evidence and clinical rationale. Each function sees only part of the problem if it works alone.

The expanding target landscape needs similar discipline. Full-Life reported human imaging with In-111 FL-261, a c-MET-targeting ligand, in ten patients with non-small cell lung cancer. Its accompanying alpha-treatment efficacy evidence was preclinical. The human imaging result creates a reason to investigate; it does not establish human therapeutic benefit.

This is where a busy congress can mislead even an informed reader. A target can be biologically interesting, visible on a scan and still have a long therapeutic development path ahead. For an investor, the next milestone depends on which of those questions has actually been answered. For a supplier, an interesting target is not yet a dependable demand forecast.

The industrial announcements started to meet that problem

The equipment story offered a concrete example. IBA unveiled NEPTIS Perform Duo at the congress on 18 October, bringing tracer development and routine production onto one synthesiser module. Its development mode uses reusable components; production retains single-use cassettes. This is a product launch supported by internal testing, not a published demonstration of customer cost savings or successful transfer between sites.

The design direction matters: fewer disconnects between developing a process and running it routinely. The next evidence would be a customer showing what happened outside the supplier's own testing. Did a process transfer? What qualification work remained? Did routine performance improve? Those answers would be more commercially useful than another installed-equipment count.

Supply was also being connected to delivery geography. In a congress-week announcement, Telix and Ekalia set out a US At-211 production framework, with the first installation intended for RLS Trevose near Philadelphia and access envisaged for third-party programmes. This was planned infrastructure, not commissioned output. The sequence from installation to qualification to reliable delivery remains the work to watch.

And measurement is part of the infrastructure too. GE HealthCare announced five collaborations to evaluate StarGuide GX across imaging and workflow. An evaluation programme cannot be booked as a completed gain in patient throughput. It does, however, identify the kind of evidence that would make a new imaging capability relevant to a functioning service.

What changes for the industry now?

The immediate implication is a more demanding definition of progress. A supply agreement, an imaging result and a new production module may all be valuable. They remove different uncertainties. Adding them together does not automatically produce a ready treatment pathway.

For developers, the priority is to identify the next decision that could invalidate the plan. That might be a target-selection question, a product specification, an analytical method or a delivery constraint. The evidence package should be organised around that decision rather than a collection of impressive but disconnected milestones.

For CDMOs and equipment suppliers, there is a potential service opportunity in helping customers move between stages: development to qualified process, one site to another, or an initial method to something that works routinely. That is our interpretation, not a finding that EANM proved suppliers can already charge more. A credible offer needs defined responsibilities and evidence from delivery.

For investors, the useful adjustment is to separate scientific progress from industrial readiness in the investment case. A programme can improve on one dimension while remaining exposed on another. The questions behind The Manufacturing Veto remain relevant even when the clinical story becomes more attractive.

The leadership implication follows from the work. A CMC leader needs to connect material choices, process changes and analytical control. Clinical and dosimetry teams need to explain which measurements support which decisions. Quality, supply and operations need a shared account of what can be released and delivered. Hiring those people against separate job descriptions, without defining the decisions they must make together, leaves the critical hand-offs unowned.

What would make this interpretation wrong?

Scarcity could remain the dominant constraint. If a programme cannot secure material at all, improving the transfer package does not solve its immediate problem. Promising clinical signals can also fail to hold up in larger studies. An equipment platform may add convenience without materially changing development time or economics.

That is why the next six to twelve months should be judged through follow-through: fuller datasets, qualified installations, successful transfers and repeatable deliveries. These are proposed diligence milestones, not promised company timelines. The full report sets out a more detailed set of tests and the countercase.

The fallout from Vienna is therefore an operating agenda. The sector has more possibilities to investigate, and clearer reasons to ask how each one becomes usable. The companies that can answer that question with evidence will be easier to underwrite, easier to partner with and better placed to turn scientific progress into something patients can receive.

Sources and scope

Analysis as of 22 October 2026, drawing on the primary announcements linked throughout. Company-reported findings have not been independently replicated here. This is a selected commercial interpretation, not a comprehensive congress review, clinical guidance or a claim of market-wide consensus. The diagrams are ProGen analytical frameworks, not quantitative forecasts. ProGen did not attend the congress.